Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBPH
Previous Symbol
CUSIPN/A
Phone508-473-5993
Debt
Debt-to-Equity RatioN/A
Current Ratio10.67
Quick Ratio10.67
Price-To-Earnings
Trailing P/E Ratio-5.36
Forward P/E Ratio-5.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales470.37
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.68 per share
Price / Book3.74
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-27,670,000.00
Net MarginsN/A
Return on Equity-58.85%
Return on Assets-42.71%
Miscellaneous
Employees21
Outstanding Shares16,430,000
Market Cap$164.99 million
OptionableNot Optionable
Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions
What is Spring Bank Pharmaceuticals' stock symbol?
Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."
How were Spring Bank Pharmaceuticals' earnings last quarter?
Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) announced its quarterly earnings data on Thursday, October, 25th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.01. View Spring Bank Pharmaceuticals' Earnings History.
When is Spring Bank Pharmaceuticals' next earnings date?
What price target have analysts set for SBPH?
4 Wall Street analysts have issued twelve-month price targets for Spring Bank Pharmaceuticals' shares. Their predictions range from $25.00 to $45.00. On average, they expect Spring Bank Pharmaceuticals' share price to reach $33.00 in the next year. This suggests a possible upside of 229.3% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.
What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.
Has Spring Bank Pharmaceuticals been receiving favorable news coverage?
Press coverage about SBPH stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spring Bank Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Spring Bank Pharmaceuticals' key competitors?
Some companies that are related to Spring Bank Pharmaceuticals include Dynavax Technologies (DVAX), Omeros (OMER), ANI Pharmaceuticals (ANIP), Inflarx (IFRX), Rocket Pharmaceuticals (RCKT), Eagle Pharmaceuticals (EGRX), Kezar Life Sciences (KZR), MacroGenics (MGNX), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Vectura Group (VEGPF), Karyopharm Therapeutics (KPTI), AMAG Pharmaceuticals (AMAG), CannTrust (CNTTF) and Assembly Biosciences (ASMB).
Who are Spring Bank Pharmaceuticals' key executives?
Spring Bank Pharmaceuticals' management team includes the folowing people:
- Mr. Martin J. Driscoll, Pres, CEO & Chairman (Age 59)
- Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 68)
- Dr. Nezam H. Afdhal, Chief Medical Officer (Age 61)
- Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 40)
- Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.
When did Spring Bank Pharmaceuticals IPO?
(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.
Who are Spring Bank Pharmaceuticals' major shareholders?
Spring Bank Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Jennison Associates LLC (4.15%), Baker BROS. Advisors LP (3.73%), BlackRock Inc. (3.68%), Vanguard Group Inc. (3.34%), Vanguard Group Inc (3.34%) and Morse Asset Management Inc (1.16%). Company insiders that own Spring Bank Pharmaceuticals stock include David Arkowitz, Kurt M Eichler and Martin J Driscoll. View Institutional Ownership Trends for Spring Bank Pharmaceuticals.
Which major investors are selling Spring Bank Pharmaceuticals stock?
Which major investors are buying Spring Bank Pharmaceuticals stock?
SBPH stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Baker BROS. Advisors LP, Sofinnova Ventures Inc, Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., Stonepine Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include David Arkowitz, Kurt M Eichler and Martin J Driscoll. View Insider Buying and Selling for Spring Bank Pharmaceuticals.
How do I buy shares of Spring Bank Pharmaceuticals?
Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spring Bank Pharmaceuticals' stock price today?
One share of SBPH stock can currently be purchased for approximately $10.02.
How big of a company is Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals has a market capitalization of $164.99 million and generates $350,000.00 in revenue each year. The company earns $-27,670,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 21 workers across the globe.
What is Spring Bank Pharmaceuticals' official website?
How can I contact Spring Bank Pharmaceuticals?
Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]
MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
